Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Jul;80(1):7–12. doi: 10.1172/JCI113065

Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

G M Hänsch, S Schönermark, D Roelcke
PMCID: PMC442194  PMID: 3597779

Abstract

The complement-mediated lysis is inefficient when complement and target cells are homologous with regard to the species. In erythrocytes from patients suffering from paroxysmal nocturnal hemoglobinuria (PNH), the species restriction is lost: PNH-erythrocytes (PNH-E) are susceptible to lysis by human complement. In human erythrocytes (huE) the species restriction is ascribed to an integral membrane protein, designated C8-binding protein (C8bp). In the present study, we tested membranes of PNH-E type III for the presence of C8bp. A protein with C8-binding capacity could not be detected. C8bp, which was isolated from the membrane of huE, inhibited the lysis of PNH-E by C5b-9 as well as the C9 polymerization. Thus, addition of C8bp restored the species restriction in PNH-E. In conclusion, we propose that lack of C8bp might represent the defect in PNH-E type III membranes, which is responsible for their enhanced lytic susceptibility towards lysis by the late complement components.

Full text

PDF
7

Images in this article

9Image
on p.9
9Image
on p.9
9Image
on p.9
9Image
on p.9
9Image
on p.9
9Image
on p.9
9Image
on p.9
10Image
on p.10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandt F., Kalthoff P. G. The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Tropenmed Parasitol. 1983 Jun;34(2):75–78. [PubMed] [Google Scholar]
  2. Chow F. L., Hall S. E., Rosse W. F., Telen M. J. Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria. Blood. 1986 Apr;67(4):893–897. [PubMed] [Google Scholar]
  3. Hammer C. H., Wirtz G. H., Renfer L., Gresham H. D., Tack B. F. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 1981 Apr 25;256(8):3995–4006. [PubMed] [Google Scholar]
  4. Hu V. W., Nicholson-Weller A. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5520–5524. doi: 10.1073/pnas.82.16.5520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hänsch G. M., Hammer C. H., Vanguri P., Shin M. L. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5118–5121. doi: 10.1073/pnas.78.8.5118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hänsch G. M., Rummel G., Gänzler F. Purification and characterization of the ninth component of rabbit complement. Complement. 1984;1(2):116–122. doi: 10.1159/000467824. [DOI] [PubMed] [Google Scholar]
  7. Hänsch G., Hammer C., Jiji R., Rother U., Shin M. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum. Immunobiology. 1983 Mar;164(2):118–126. doi: 10.1016/S0171-2985(83)80003-5. [DOI] [PubMed] [Google Scholar]
  8. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  9. Logue G. L., Rosse W. F., Adams J. P. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest. 1973 May;52(5):1129–1137. doi: 10.1172/JCI107279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Monahan J. B., Sodetz J. M. Binding of the eighth component of human complement to the soluble cytolytic complex is mediated by its beta subunit. J Biol Chem. 1980 Nov 25;255(22):10579–10582. [PubMed] [Google Scholar]
  12. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  13. Nicholson-Weller A., March J. P., Rosenfeld S. I., Austen K. F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066–5070. doi: 10.1073/pnas.80.16.5066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Packman C. H., Rosenfeld S. I., Jenkins D. E., Jr, Leddy J. P. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes. J Immunol. 1980 Jun;124(6):2818–2823. [PubMed] [Google Scholar]
  15. Packman C. H., Rosenfeld S. I., Jenkins D. E., Jr, Thiem P. A., Leddy J. P. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. J Clin Invest. 1979 Aug;64(2):428–433. doi: 10.1172/JCI109479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pangburn M. K., Schreiber R. D., Trombold J. S., Müller-Eberhard H. J. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med. 1983 Jun 1;157(6):1971–1980. doi: 10.1084/jem.157.6.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Parker C. J., Baker P. J., Rosse W. F. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1982 Feb;69(2):337–346. doi: 10.1172/JCI110457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Parker C. J., Wiedmer T., Sims P. J., Rosse W. F. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest. 1985 Jun;75(6):2074–2084. doi: 10.1172/JCI111927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Podack E. R., Tschopp J. Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem. 1982 Dec 25;257(24):15204–15212. [PubMed] [Google Scholar]
  20. Podack E. R., Tschopp J. Membrane attack by complement. Mol Immunol. 1984 Jul;21(7):589–603. doi: 10.1016/0161-5890(84)90044-0. [DOI] [PubMed] [Google Scholar]
  21. Rosenfeld S. I., Jenkins D. E., Jr, Leddy J. P. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b. J Immunol. 1985 Jan;134(1):506–511. [PubMed] [Google Scholar]
  22. Rosenfeld S. I., Jenkins D. E., Jr, Leddy J. P. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes. J Exp Med. 1986 Oct 1;164(4):981–997. doi: 10.1084/jem.164.4.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rosenfeld S. I., Packman C. H., Jenkins D. E., Jr, Countryman J. K., Leddy J. P. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells. J Immunol. 1980 Nov;125(5):2063–2068. [PubMed] [Google Scholar]
  24. Rosse W. F., Dacie J. V. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest. 1966 May;45(5):736–748. doi: 10.1172/JCI105388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rosse W. F., Logue G. L., Adams J., Crookston J. H. Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1974 Jan;53(1):31–43. doi: 10.1172/JCI107551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rosse W. F. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1973 Mar;24(3):327–342. doi: 10.1111/j.1365-2141.1973.tb01657.x. [DOI] [PubMed] [Google Scholar]
  27. Rother U., Hänsch G., Rauterberg E. W., Jungfer H., Rother K. Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity of low pH or low ionic strength. Z Immunitatsforsch Immunobiol. 1978 Dec;155(2):118–129. [PubMed] [Google Scholar]
  28. Schreiber A. D. Paroxysmal nocturnal hemoglobinuria revisited. N Engl J Med. 1983 Sep 22;309(12):723–725. doi: 10.1056/NEJM198309223091209. [DOI] [PubMed] [Google Scholar]
  29. Schönermark S., Rauterberg E. W., Shin M. L., Löke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol. 1986 Mar 1;136(5):1772–1776. [PubMed] [Google Scholar]
  30. Shin M. L., Hänsch G., Hu V. W., Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol. 1986 Mar 1;136(5):1777–1782. [PubMed] [Google Scholar]
  31. Staros J. V. N-hydroxysulfosuccinimide active esters: bis(N-hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry. 1982 Aug 17;21(17):3950–3955. doi: 10.1021/bi00260a008. [DOI] [PubMed] [Google Scholar]
  32. Yamamoto K. I., Gewurz G. The complex of C5b and C6: isolation, characterization, and identification of a modified form of C5b consisting of three polypeptide chains. J Immunol. 1978 Jun;120(6):2008–2015. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES